Lisa Latven

Affiliations

Mirati Therapeutics, Inc., San Diego, CA, USA.

Réseau de co-auteurs

Peter Olson 2 collaborations

Pavlos Msaouel 1 collaboration

Randy F Sweis 1 collaboration

Manojkumar Bupathi 1 collaboration

Elisabeth Heath 1 collaboration

Oscar B Goodman 1 collaboration

Christopher J Hoimes 1 collaboration

Matthew I Milowsky 1 collaboration

Nancy Davis 1 collaboration

Arash Rezazadeh Kalebasty 1 collaboration

Joel Picus 1 collaboration

David Shaffer 1 collaboration

Shifeng Mao 1 collaboration

Nabil Adra 1 collaboration

Jeffrey Yorio 1 collaboration

Sunil Gandhi 1 collaboration

Petros Grivas 1 collaboration

Arlene Siefker-Radtke 1 collaboration

Rui Yang 1 collaboration

Curtis D Chin 1 collaboration

Hirak Der-Torossian 1 collaboration

Amir Mortazavi 1 collaboration

Gopa Iyer 1 collaboration

Kai He 1 collaboration

David Berz 1 collaboration

Shirish M Gadgeel 1 collaboration

Wade T Iams 1 collaboration

Debora S Bruno 1 collaboration

Collin M Blakely 1 collaboration

Alexander I Spira 1 collaboration

Manish R Patel 1 collaboration

David M Waterhouse 1 collaboration

Donald A Richards 1 collaboration

Anthony Pham 1 collaboration

Robert Jotte 1 collaboration

David S Hong 1 collaboration

Edward B Garon 1 collaboration

Anne Traynor 1 collaboration

Xiaohong Yan 1 collaboration

Ronald Shazer 1 collaboration

Ticiana A Leal 1 collaboration

Lisa Latven

Affiliations

Publications (2)

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.

Réseau de co-auteurs